Portal de investigación
Systemic management of malignant meningiomas: A comparative survival and molecular marker analysis between Octreotide in combination with Everolimus and Sunitinib
Fecha de publicación:
Fecha Ahead of Print:
Autores organización
Autores
- Ruiz-Patiño, A
- Zatarain-Barrón, ZL
- Jiménez, E
- Mejía, JA
- Ramón, JF
- Useche, N
- Bermúdez, S
- Pineda, D
- Cifuentes, H
- Ricaurte, L
- Pino, LE
- Balaña, C
- Arrieta, O
Unidades de investigación
Resumen
Purpose To compare the effectiveness of octreotide/everolimus vs. sunitinib for the systemic treatment of recurrent aggressive meningiomas. Methods 31 patients with recurrent or refractory WHO II or WHO III meningiomas were examined in two reference centers in Colombia. Patients who had systemic treatment (sunitinib, everolimus/octreotide) and a complete follow-up were included. Overall survival (OS), progression-free survival (PFS) and toxicities were evaluated. Additionally, tissue samples were examined for PDGFR beta and VEGFR2, their expression was correlated with outcomes. Results Twenty-two patients (72%) were female with a median age of 55 years (SD +/- 15.3). The most prevalent histology was anaplastic meningioma in 20 patients (65%) with 48% of patients suffering from three previous relapses before the start of systemic treatment. A total of 14 patients received combination therapy with octreotide/everolimus, 11 received sunitinib and the remaining 6 received other second-line agents. Median OS was 37.3 months (95% CI 28.5-42.1) and the PFS during the treatment with everolimus/octreotide (EO) and sunitinib (Su) was 12.1 months (95% CI 9.2-21.1) and 9.1 months (95% CI 6.8-16.8); p = 0.43), respectively. The OS of the group treated with the EO -> Su -> Bev sequence (1st/2nd/3rd line) was 6.5 months longer than the Su -> EO -> Bev sequence (36.0 vs. 29.5 months) (p = 0.0001). When analyzing molecular markers, the positive PDGFR beta and negative VEGFR2 expression were associated with longer survival both in OS and PFS. Conclusion Sunitinib and octreotide/everolimus have similar efficacy and safety in the systemic management of refractory meningioma. VEGFR2 and PDGFR beta expression are associated with better outcomes.
Datos de la publicación
- ISSN/ISSNe:
- 1932-6203, 1932-6203
- Tipo:
- Article
- Páginas:
- -
- PubMed:
- 31220093
- Enlace a otro recurso:
- www.scopus.com
Plos One Public Library of Science
Citas Recibidas en Web of Science: 16
Citas Recibidas en Scopus: 26
Documentos
- No hay documentos
Filiaciones
Keywords
- Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease-Free Survival; Everolimus; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Male; Meningeal Neoplasms; Meningioma; Middle Aged; Neoplasm Proteins; Octreotide; Receptor, Platelet-Derived Growth Factor beta; Retrospective Studies; Sunitinib; Survival Rate; Vascular Endothelial Growth Factor Receptor-2; everolimus; octreotide; platelet derived growth factor beta receptor; sunitinib; vasculotropin receptor 2; antineoplastic agent; everolimus; KDR protein, human; octreotide; PDGFRB protein, human; platelet derived growth factor beta receptor; sunitinib; tumor marker; tumor protein; vasculotropin receptor 2; adult; adverse outcome; Article; cancer combination chemotherapy; cancer survival; clinical article; Colombia; controlled study; drug dose reduction; drug efficacy; drug safety; edema; fatigue; female; human; hypothyroidism; male; malignant meningioma; midd
Proyectos asociados
Citar la publicación
Cardona AF,Ruiz A,Zatarain ZL,Hakim F,Jiménez E,Mejía JA,Ramón JF,Useche N,Bermúdez S,Pineda D,Cifuentes H,Rojas L,Ricaurte L,Pino LE,Balaña C,Arrieta O. Systemic management of malignant meningiomas: A comparative survival and molecular marker analysis between Octreotide in combination with Everolimus and Sunitinib. PLoS ONE. 2019. 14. (6):e0217340. IF:2,740. (2).